SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is generating significant social media buzz as traders debate its potential as a high-growth Layer-1 alternative to Solana, with many highlighting its integration into institutional products and recent developments within its ecosystem. Community discussions are split between bullish sentiment fueled by institutional accumulation and skepticism from those wary of market volatility and recent price fluctuations.

StupidCoin

StupidCoin is gaining significant traction within the Solana ecosystem as traders rally behind its active community-led development and viral marketing efforts. Enthusiasts are highlighting the project's recent growth, community collaborations, and ecosystem integrations as key drivers for heightened market interest.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a positive pre-BLA meeting with the FDA, which aligned on the submission path and label strategy for sonelokimab in hidradenitis suppurativa. Community discussion is focused on the upcoming VELA 52-week durability data and the potential for a favorable BLA submission in late 2026, with investors actively debating the competitive positioning against existing treatments and anticipating a potential price re-rating.

Got that dog in you? - Fueled by a mantra of tokenized self-belief, doginme is representative of the community's collective efforts to embrace and embolden that dog in them. doginme stands for knowing yourself and having that unshakable drive to keep pushing forward. doginme was originally launched in February 2024 when the Farcaster founder was asked if he owned a dog, to which he replied affirmatively: "no but I got that dog in me"

doginme

DOGINME is trending as the community rallies around its unique 'tokenized self-belief' narrative, emphasizing grit and holding conviction during market volatility. Enthusiasts are actively highlighting the project's growth on the Base chain and speculating on potential exchange listings, with many members bonding over the core 'I got that dog in me' spirit.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

The community is actively debating the potential for a breakout or consolidation phase as $PEPE trends alongside broader meme coin volatility. Traders are expressing mixed sentiments, with some focusing on long-term accumulation strategies during pullbacks while others remain skeptical about the coin's price stability.

Honda Motor Co., Ltd. engages in the manufacture and sale of automobiles, motorcycles, and power products. It operates through the following segments: Automobile, Motorcycle, Financial Services, and Power Product and Other Businesses. The Automobile segment manufactures and sells automobiles and related accessories. The Motorcycle segment handles all-terrain vehicles, motorcycle business, and related parts. The Financial Services segment provides financial and insurance services. The Power Product and Other Businesses segment offers power products and relevant parts. The company was founded by Soichiro Honda on September 24, 1948 and is headquartered in Tokyo, Japan.

Honda Motor - ADR

Honda Motor Co., Ltd.

Honda is experiencing significant volatility as the company grapples with an abrupt cancellation of its AFEELA EV joint venture with Sony and a massive writedown of its electric vehicle strategy. Community sentiment is mixed, with some investors focusing on the company's long-term reliability and value in hybrid markets, while others express frustration over its lagging pace in the global EV race compared to Chinese competitors.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing heightened trading volume and speculative momentum as investors rotate into IoT and Japanese-focused blockchain projects, while long-term supporters remain focused on ecosystem expansion and technical breakout patterns despite mixed sentiment. The community continues to debate the project's long-term utility versus its history of volatility, with many users actively accumulating positions in anticipation of potential future developments.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

Fartcoin is seeing intense social media chatter driven by a mix of speculative trading, humorous engagement, and comparisons to other low-cap Solana assets. Investors are actively debating the token's price stability and speculative potential, while frequent community cross-references to other memecoins highlight a highly active, trend-focused environment.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is experiencing a surge in social media activity and trader interest as the community anticipates potential token burns and watches for breakout momentum. Investors are actively debating the coin's long-term utility while leveraging its high volatility to capitalize on recent price action within the Solana ecosystem.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending following the announcement of a pivotal Phase 3 design for its lead drug candidate, CAD-1005, aimed at treating heparin-induced thrombocytopenia. While some investors are optimistic about the upcoming trial path and orphan drug designation, the community is currently debating the stock's volatility and widespread skepticism surrounding the heavy automated bot activity on discussion boards.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>First-quarter revenue growth was driven by a 23% increase in net sales of Lupkynis, an oral treatment for adults with active lupus nephritis, a serious kidney disease.</li><li>The biotech firm reiterated its FY2026 revenue guidance of $315 million to $325 million.</li><li>Aurinia’s earnings of $0.25 per share topped analysts’ estimates of $0.20 per share.</li></ul>Shares of Aurinia Pharmaceuticals (AUPH) fell more than 10% on Thursday, marking their steepest single-day drop in over nine months, as investors appeared unsettled by the lack of an earnings call and limited pipeline updates despite the company posting a first-quarter earnings beat.The report marked Aurinia’s first quarterly update since a <a href="https://stocktwits.com/news-articles/markets/equity/auph-stock-jumps-ceo-shake-up-aurinia-tang-greenleaf/cZ3mLhSRI0p">sweeping leadership overhaul</a> in March. The company appointed industry veteran Kevin Tang as CEO to replace Peter Greenleaf, who served in the position for seven years. The company also named Michael Hearne as CFO, Ryan Cole as COO, and Thomas Wei as Chief Scientific Officer.<h2 class="st-heading-2">AUPH Sees Revenue Growth Across All Segments</h2>Aurinia reported first-quarter revenue of $77.7 million, up 24% year over year and ahead of Wall Street expectations of about $77 million, according to Fiscal.ai data. The company posted earnings of $0.25 per share, topping analysts’ estimates of $0.20 per share.Revenue growth was driven by a 23% increase in net sales of Lupkynis, an oral treatment for adults with active lupus nephritis, a serious kidney disease. Meanwhile, revenue from Aurinia’s licensing, collaboration, and royalty agreement with Otsuka rose 64% to $4.1 million.The biotech firm reiterated its full-year 2026 revenue guidance of $315 million to $325 million, up 11% to 15% year over year.&nbsp;&nbsp;<h2 class="st-heading-2">Retail Questions Lack Of Information</h2>Despite the sharp intraday fall, retail sentiment for <a href="https://stocktwits.com/symbol/AUPH">AUPH</a> turned ‘bullish’ from ‘bearish’ a day earlier, while message volumes were ‘high.’One user questioned the lack of an earnings call and asked why the company did not provide updates on its clinical trials for Aritinercept, an autoimmune disease drug candidate under development for three potential uses. The company had earlier announced plans to begin a clinical study of Aritinercept in the first half of 2026.<stembedurl>https://stocktwits.com/Whpbauer/message/652570535</stembedurl>Another user remained bullish but said they hoped for more clinical updates and merger information.<stembedurl>https://stocktwits.com/Prosperity1_/message/652565629</stembedurl>The stock has shed around 10% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/kala-stock-record-low-reverse-split/cZXbKgSReQX">KALA Stock Hits Record Low – Firm Announces Reverse Split After Shares Fail To Surpass The $1 Mark</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aurinia Pharmaceuticals logo is seen displayed on a smartphone screen

AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors

Aurinia reported Q1 revenue of $77.7 million, ahead of Wall Street expectations of about $77 million, according to Fiscal.ai data.

Equity

Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of +38.89% and +0.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals Inc. Profit Advances In Q1

(RTTNews) - Aurinia Pharmaceuticals Inc. (AUP.V) revealed earnings for its first quarter that Increased, from last year...

Guardian Pharmacy Services (GRDN) Q1 Earnings and Revenues Surpass Estimates

Guardian Pharmacy (GRDN) delivered earnings and revenue surprises of +20.83% and +2.10%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals (AUPH) to Release Quarterly Earnings on Monday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at...

Short Interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Decreases By 15.7%

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the target of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totaling 9,112,230 shares, a decrease of 15.7% from the March 31st total of 10,809,496 shares...

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) (TSE:AUP) have been assigned a consensus rating of "Hold" from the six ratings firms that are covering the company, MarketBeat...

Select Medical (SEM) Lags Q1 Earnings Estimates

Select Medical (SEM) delivered earnings and revenue surprises of -15.91% and +1.54%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals (NASDAQ:AUPH) Hits New 1-Year High  - Still a Buy?

Aurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 1-Year High - Time to Buy...

Tudor Investment Corp ET AL Buys Shares of 65,964 Aurinia Pharmaceuticals Inc $AUPH

Tudor Investment Corp ET AL bought a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) (TSE:AUP) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 65,964 shares of the biotechnology company's stock, valued...

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

AUPH
Aurinia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AUPH News

AUPHAurinia Pharmaceuticals Inc